Layer Health

Cover Block

PUBLIC

Attribute	Value
Name	Layer Health
Tagline	AI platform automating chart review from unstructured EHR data
Headquarters	Brookline, Massachusetts
Founded	2023
Stage	Series A
Business Model	SaaS
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Series A (total disclosed ~$25,000,000)

Links

PUBLIC

• Website: https://www.layerhealth.com/
• LinkedIn: https://www.linkedin.com/company/layer-health

Executive Summary

PUBLIC

Layer Health is building an AI platform to automate the extraction of clinical insights from unstructured electronic health records, a foundational but historically manual process that represents a significant cost and data bottleneck for healthcare systems [Layer Health, Mar 2025]. The company's position as an MIT spinout with a technically deep founding team and a Series A from specialized healthtech investors warrants attention for its potential to scale a high-accuracy solution in a regulated, high-stakes domain. Founded in 2023, the company emerged from research at MIT and Harvard Medical School, focusing on applying large language models to the specific challenge of chart review [MIT News, Mar 2025].

Its flagship product, Distill, is positioned as a general-purpose AI layer that can be applied to diverse tasks, from clinical registry reporting to revenue cycle management, by interpreting free-text clinician notes [Layer Health, Nov 2023]. The founding team's composition is a core differentiator, combining a leading academic AI researcher, clinical informatics expertise from a practicing physician, and engineering talent from major technology firms [Define Ventures, Unknown]. With $25 million in total disclosed funding, including a $21 million Series A led by Define Ventures in March 2025, the company operates on a SaaS model and is scaling its commercial efforts [MobiHealthNews, Nov 2023] [Layer Health, Mar 2025].

The next 12-18 months will test whether early announced partnerships with health systems like Intermountain Health translate into scaled, multi-year deployments and measurable operational savings, proving the platform's utility beyond pilot projects.

Data Accuracy: YELLOW -- Core company facts and funding are confirmed via company announcements and investor materials; team details are partially corroborated by LinkedIn and academic profiles.

Taxonomy Snapshot

Axis	Classification
Stage	Series A
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Series A (total disclosed ~$25,000,000)

Company Overview

PUBLIC

Layer Health emerged in 2023 from a collaboration between MIT artificial intelligence researchers and clinical informaticists, formalizing a research effort to apply large language models to the persistent problem of extracting structured data from electronic health records [MIT News, Mar 2025]. The company is headquartered in Brookline, Massachusetts, with a founding team whose academic and technical credentials are central to its narrative [Layer Health, Mar 2025]; [LinkedIn, Unknown].

Its initial seed round of $4 million in November 2023, backed by GV and General Catalyst, served as a public launch, introducing its Distill platform aimed at automating chart review [MobiHealthNews, Nov 2023]. A subsequent Series A round of $21 million in March 2025, led by Define Ventures, provided capital to scale the team and platform [Layer Health, Mar 2025]. Key operational milestones since founding include announced partnerships with health systems like White Plains Hospital and Intermountain Health, as well as a research collaboration with the American Cancer Society, all focused on deploying its AI for clinical registry reporting and data abstraction [Layer Health, Unknown]; [Layer Health, Unknown]; [Layer Health, Unknown].

Data Accuracy: YELLOW -- Company announcements and investor materials are primary; some team details are self-reported or inferred from LinkedIn.

Product and Technology

MIXED Layer Health’s product thesis is built on a single, high-friction task: automating the extraction of structured data from the unstructured narrative of electronic health records. The company’s flagship platform, Distill, is positioned as a general-purpose tool for any workflow that requires manual chart review, from clinical quality reporting to research data curation [Layer Health, Nov 2023]. This positioning suggests a platform approach rather than a point solution for a single use case.

The technical claim is clinician-level accuracy without predefined rules, implying a reliance on large language models trained on proprietary clinical datasets [Layer Health]. The platform is designed to integrate into existing healthcare IT environments, ingesting clinical notes at scale to perform tasks the company groups into three categories. Clinical and administrative. This includes support for clinical registry submission, care pathway adherence analytics, and care gap identification [Elion]. Revenue cycle. The product is cited for use in clinical document improvement, a process directly tied to medical coding and billing accuracy [Layer Health, Nov 2023]. Research. Distill is also applied to curate real-world evidence and, in a partnership with the American Cancer Society, to accelerate data abstraction for cancer research [Layer Health].

Public announcements from mid-2025 provide the clearest view of product-market fit. A multi-year deployment agreement with Intermountain Health, which included a strategic investment, indicates a move beyond pilot projects toward embedded, operational use [Layer Health]. Another announced partnership with White Plains Hospital specifically targets the automation of clinical registry reporting, a known administrative burden for health systems [Layer Health]. These deals, framed as partnerships with strategic investors, serve as de facto public case studies, though specific performance metrics remain [PRIVATE].

Data Accuracy: YELLOW -- Product claims are sourced from company announcements and a limited set of third-party reports; technical performance claims (e.g., "clinician-level accuracy") are not independently verified.

Market Research

PUBLIC

The market for AI-powered clinical data abstraction is coalescing around a single, expensive bottleneck: the manual review of unstructured electronic health records. This process, essential for quality reporting, research, and billing, consumes thousands of clinician hours annually and is a primary target for health system operational spending.

Third-party market sizing specific to AI for chart review is not publicly available in the cited sources. However, the broader adjacent markets for healthcare data analytics and real-world evidence provide a relevant analog. According to Grand View Research, the global real-world evidence solutions market was valued at approximately $1.9 billion in 2023 and is projected to grow at a compound annual rate of 8.5% through 2030 [Grand View Research, 2024]. The demand is driven by regulatory requirements for post-market surveillance and the pharmaceutical industry's need for efficient trial design and outcomes research, both of which rely heavily on data extracted from patient charts.

Key demand drivers for automation are well-documented. Regulatory mandates from the Centers for Medicare & Medicaid Services (CMS) and other bodies require extensive quality reporting, which traditionally necessitates manual chart abstraction. Concurrently, health systems face sustained pressure to control labor costs and reduce clinician burnout, making the automation of repetitive documentation tasks a high priority. The proliferation of real-world evidence studies in life sciences creates a secondary, revenue-generating use case for health systems that can reliably monetize their data.

Substitute markets include legacy rules-based abstraction software and large-scale manual review services, both of which are established but less scalable. The primary regulatory force is the Health Insurance Portability and Accountability Act (HIPAA), which governs data privacy and security for any platform handling patient information. Macro forces include the ongoing consolidation of health systems, which creates larger, more complex data environments, and the accelerated adoption of cloud infrastructure in healthcare, which enables the deployment of compute-intensive AI models.

Metric	Value
Real-World Evidence Solutions (2023)	1.9 $B
Projected Growth Rate (2024-2030)	8.5 % CAGR

The adjacent market growth for real-world evidence, at nearly 8.5% annually, signals sustained investment in the underlying data infrastructure Layer Health aims to automate. While not a direct measure of the chart review software TAM, it indicates the financial value placed on the outputs of the process.

Data Accuracy: YELLOW -- Market sizing is drawn from an analogous, broader sector report; specific TAM for AI chart review is not independently confirmed.

Competitive Landscape

MIXED

Layer Health enters a crowded but fragmented market for healthcare data extraction, positioning its Distill platform not as a point solution for a single task but as a general-purpose AI layer for chart review across clinical, administrative, and research workflows.

Given the absence of named, specific competitors in the captured sources, a direct comparison table cannot be constructed. The competitive analysis must therefore proceed on a segment-by-segment basis, mapping the landscape by category of solution rather than by individual company names.

The competitive map breaks into three primary segments. First, legacy healthcare IT incumbents like Epic and Cerner offer native reporting tools and, increasingly, AI modules, but these are often rule-based and tightly integrated with their own EHR ecosystems, creating interoperability challenges for multi-system health networks. Second, a wave of specialized AI startups has emerged, each targeting a specific use case within chart review, such as clinical trial matching, quality measure abstraction, or cancer registry coding. Third, adjacent substitutes include large technology companies offering general-purpose large language models (LLMs) and consulting firms that provide manual data abstraction services, which represent both a threat and a potential partnership channel.

Layer Health’s defensible edge today appears rooted in its founding team’s academic and clinical pedigree, which serves as a proxy for technical moat and early credibility in a regulated domain. CEO David Sontag’s research authority (over 24,000 citations [Google Scholar, 2026]) and the inclusion of a practicing physician, Steven Horng, as a co-founder signal a deep understanding of both AI model development and clinical workflow realities. This talent edge is perishable, however, as larger incumbents can acquire similar expertise, and it must be translated into tangible, scaled deployments to build a data advantage. The recent Series A capital from Define Ventures, GV, and General Catalyst provides a war chest to out-execute smaller point-solution rivals in the near term [Layer Health, Mar 2025].

The company’s most significant exposure lies in distribution and integration depth. While legacy EHR vendors own the primary system of record and can embed AI features directly into clinician workflows, Layer Health must sell into IT departments and navigate complex procurement cycles as an external vendor. Furthermore, its generalist positioning,tackling everything from registry submissions to revenue cycle management,could leave it vulnerable to more focused competitors that achieve deeper domain optimization in a single, high-value vertical like oncology or cardiology. Without published benchmarks against these specialists, the claim of "clinician-level accuracy" remains a company assertion [Layer Health, Unknown].

The most plausible 18-month scenario hinges on whether Layer Health can convert its announced partnerships into scaled, multi-year deployments that generate proprietary data feedback loops. A winner in this scenario would be a company that successfully bundles several adjacent use cases into a single platform contract with a major health system, such as Intermountain Health, thereby reducing vendor sprawl and proving ROI across departments [Layer Health, Unknown]. A loser would be a startup that remains a point solution for a single administrative task, as health systems consolidate budgets and seek platform vendors. Layer Health’s early moves with White Plains Hospital for registry reporting and the American Cancer Society for research abstraction suggest a strategy aimed at this bundled platform outcome [Layer Health, Unknown].

Data Accuracy: YELLOW -- Competitive mapping is inferred from market structure; specific competitor names and differentiators are not publicly cited in source materials.

Opportunity

PUBLIC If Layer Health's AI can reliably automate the manual, high-cost process of clinical chart review, it unlocks a multi-billion dollar wedge into the operational and analytical workflows of every major health system. The company's opportunity rests on converting a core academic and clinical team into a scalable enterprise platform that moves from automating discrete tasks to becoming the essential data layer for healthcare operations.

The headline opportunity is to become the default AI-powered abstraction layer for the entire healthcare data supply chain. Today, extracting structured insights from electronic health records for registries, quality reporting, and research is a labor-intensive, error-prone bottleneck. Layer Health's Distill platform aims to replace this manual work with clinician-level AI, a claim the company makes directly [Layer Health]. This outcome is reachable because the initial use cases, like clinical registry reporting, are not just theoretical; the company has announced deployments with health systems such as White Plains Hospital and a multi-year agreement with Intermountain Health [Layer Health]. These early partnerships demonstrate a willingness from established providers to integrate AI into core, regulated workflows, providing a critical beachhead for expansion.

From this beachhead, several concrete growth scenarios emerge for scaling the platform's footprint and revenue.

Scenario	What happens	Catalyst	Why it's plausible
Registry Dominance	Distill becomes the dominant tool for automating submissions to major clinical quality registries (e.g., STS, NCDR).	A formal endorsement or partnership with a major registry body.	The partnership with the American Cancer Society to accelerate data abstraction for cancer research establishes a template for working with large, data-intensive organizations [Layer Health].
Health System OS	The platform expands from discrete tasks to become the central operating layer for all non-clinical chart review across a health system's administrative, financial, and research functions.	A flagship health system (like Intermountain) publicly attributes significant cost savings or revenue gains to the platform.	The Series A round included MultiCare Capital Partners, the investment arm of a large health system, suggesting strategic alignment and a potential blueprint for system-wide deployment [Layer Health, Mar 2025].
Life Sciences Data Partner	Layer Health evolves into a primary vendor for curating real-world evidence datasets from EHRs for pharmaceutical and medical device companies.	A major pharma company licenses a proprietary dataset curated by Distill.	The company's stated use cases already include "curation of real-world evidence" [Layer Health, Nov 2023], and investors like Define Ventures and GV have deep life sciences portfolios, indicating a clear path to this market [Layer Health, Mar 2025].

Compounding for Layer Health looks like a data and trust flywheel. Each new health system deployment feeds the AI models with more diverse, real-world clinical notes, which should, in theory, improve accuracy and generalizability. This technical improvement lowers the cost of serving the next customer and expands the scope of tasks the platform can reliably automate. More importantly, each successful deployment with a reputable institution builds the clinical trust necessary to sell into adjacent departments and peer organizations. The strategic investment from Intermountain Health, a recognized innovator, acts as a powerful reference that can catalyze this flywheel [Layer Health].

The size of the win can be framed by looking at the value of the workflows being automated. While a direct public comparable is scarce, the market for healthcare data abstraction and clinical registry services is measured in billions of dollars annually, serviced by a fragmented mix of manual labor and legacy software. If Layer Health captured a meaningful portion of this spend by becoming the preferred automation layer for even a segment of the top 200 U.S. health systems, the company's scale could approach that of successful healthcare IT infrastructure peers. In a Registry Dominance scenario, where the platform becomes embedded in high-value reporting mandates, the company could build a business with annual recurring revenue in the hundreds of millions of dollars. This is a scenario-based outcome, not a forecast, but it illustrates the substantial enterprise value accessible if the technology executes against a clear and costly pain point.

Data Accuracy: YELLOW -- Core opportunity thesis is supported by announced partnerships and investor composition, but scale and financial impact remain unproven in public disclosures.

Sources

PUBLIC

1. [Define Ventures, Unknown] Define Ventures | https://www.defineventures.com/

2. [Elion, Unknown] Elion | https://www.elion.com/

3. [Google Scholar, 2026] Google Scholar | https://scholar.google.com/citations?user=5LJqKcMAAAAJ

4. [Grand View Research, 2024] Grand View Research | https://www.grandviewresearch.com/industry-analysis/real-world-evidence-rwe-market

5. [Layer Health, Mar 2025] Layer Health Raises $21 Million Series A to Transform Medical Chart Review Using AI | https://www.layerhealth.com/resources/layer-health-raises-series-a

6. [Layer Health, Nov 2023] Introducing Layer Health | https://www.layerhealth.com/resources/introducing-layer-health-seed

7. [Layer Health, Unknown] Layer Health | https://www.layerhealth.com/

8. [Layer Health, Unknown] The American Cancer Society and Layer Health to Accelerate Data Abstraction for Cancer Research | https://www.layerhealth.com/resources/american-cancer-society-partners-with-layerhealth

9. [Layer Health, Unknown] Layer Health Receives Strategic Investment and Multi-Year AI Deployment with Intermountain Health | https://www.layerhealth.com/resources/https-www-einpresswire-com-article-822674694-layer-health-receives-strategic-investment-and-multi-year-ai-deployment-with-intermountain-health-n-2

10. [Layer Health, Unknown] White Plains Hospital Teams with Layer Health to Streamline Clinical Registry Reporting | https://www.layerhealth.com/resources/white-plains-hospital-teams-with-layer-health-to-streamline-clinical-registry-reporting

11. [LinkedIn, Unknown] David Sontag - Layer Health | https://www.linkedin.com/in/david-sontag

12. [MIT News, Mar 2025] MIT News | https://news.mit.edu/

13. [MobiHealthNews, Nov 2023] Layer Health launches with $4M | https://www.mobihealthnews.com/news/layer-health-launches-4m-google-ventures-general-catalyst